Filing Details
- Accession Number:
- 0001453687-24-000132
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2024-11-18 19:32:36
- Reporting Period:
- 2024-11-14
- Accepted Time:
- 2024-11-18 19:32:36
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1453687 | Cartesian Therapeutics Inc. | RNAC | Pharmaceutical Preparations (2834) | 000000000 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 2000284 | Metin Kurtoglu | C/O Cartesian Therapeutics, Inc. 7495 New Horizon Way Frederick MD 21703 | Chief Technology Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2024-11-14 | 25,900 | $1.41 | 76,933 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2024-11-14 | 21,900 | $16.33 | 55,033 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2024-11-14 | 4,000 | $17.06 | 51,033 | No | 4 | S | Direct | |
| Common Stock | Acquisiton | 2024-11-15 | 22,068 | $1.41 | 73,101 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2024-11-15 | 22,068 | $17.20 | 51,033 | No | 4 | S | Direct | |
| Common Stock | Acquisiton | 2024-11-18 | 34,400 | $1.41 | 85,433 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2024-11-18 | 16,672 | $18.19 | 68,761 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2024-11-18 | 17,728 | $18.58 | 51,033 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (Right to Buy) | Disposition | 2024-11-14 | 25,900 | $0.00 | 25,900 | $1.41 |
| Common Stock | Stock Option (Right to Buy) | Disposition | 2024-11-15 | 22,068 | $0.00 | 22,068 | $1.41 |
| Common Stock | Stock Option (Right to Buy) | Disposition | 2024-11-18 | 34,400 | $0.00 | 34,400 | $1.41 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 187,920 | 2026-11-06 | No | 4 | M | Direct | |
| 165,852 | 2026-11-06 | No | 4 | M | Direct | |
| 131,452 | 2026-11-06 | No | 4 | M | Direct |
Footnotes
- The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $16.00 to $16.65. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $17.00 to $17.12. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $17.00 to $17.42. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $17.50 to $18.49. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $18.50 to $18.69. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- The option was fully vested and exercisable upon the closing of the merger described in footnote 7.
- On November 13, 2023, the Issuer acquired the private Delaware corporation which was then known as Cartesian Therapeutics, Inc. ("Old Cartesian") in accordance with the terms of an Agreementand Plan of Merger, dated November 13, 2023. Options to purchase Old Cartesian common stock held by the reporting person were converted into options to purchase shares of the Issuer's Series APreferred Stock in connection with the merger. On April 8, 2024, these options previously exercisable for shares of Series A Preferred Stock became exercisable solely for shares of the Issuer's CommonStock.
Billionaire Hedge Funds
